tetano
Editor, Senior Moderator
Front Med (Lausanne)
. 2022 Jan 7;8:793437.
doi: 10.3389/fmed.2021.793437. eCollection 2021.
Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus
Limin S Ding[SUP] 1 2 [/SUP], Yuhang Zhang[SUP] 1 2 [/SUP], Dan Wen[SUP] 1 3 [/SUP], Jianbo Ma[SUP] 4 [/SUP], Hao Yuan[SUP] 2 4 [/SUP], Hongyue Li[SUP] 1 2 [/SUP], Shuguang Duo[SUP] 5 [/SUP], Fei Yuan[SUP] 1 [/SUP], Yong E Zhang[SUP] 2 4 6 [/SUP], Aihua Zheng[SUP] 1 2 7 [/SUP]
Affiliations
Abstract
SARS-CoV-2 is an emerging coronavirus threatening human health and the economy worldwide. As an RNA virus, variants emerge during the pandemic and potentially influence the efficacy of the anti-viral drugs and vaccines. Eight spike variants harboring highly recurrent mutations were selected and introduced into a replication-competent recombinant VSV in place of the original G protein (rVSV-SARS-CoV-2). The resulting mutant viruses displayed similar growth curves in vitro as the wild-type virus and could be neutralized by sera from convalescent COVID-19 patients. Several variants, especially Beta strain, showed resistance to human neutralizing monoclonal antibodies targeting the receptor-binding domain (RBD). A single dose of rVSV-SARS-CoV-2 Beta variant could elicit enhanced and broad-spectrum neutralizing antibody responses in human ACE2 knock-in mice and golden Syrian hamsters, while other mutants generated antibody levels comparable to the wild-type. Therefore, our results will be of value to the development of next-generation vaccines and therapeutic antibodies.
Keywords: SARS-CoV-2; VSV; antigenicity; immunogenicity; infectivity; mutation; spike; variant
. 2022 Jan 7;8:793437.
doi: 10.3389/fmed.2021.793437. eCollection 2021.
Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus
Limin S Ding[SUP] 1 2 [/SUP], Yuhang Zhang[SUP] 1 2 [/SUP], Dan Wen[SUP] 1 3 [/SUP], Jianbo Ma[SUP] 4 [/SUP], Hao Yuan[SUP] 2 4 [/SUP], Hongyue Li[SUP] 1 2 [/SUP], Shuguang Duo[SUP] 5 [/SUP], Fei Yuan[SUP] 1 [/SUP], Yong E Zhang[SUP] 2 4 6 [/SUP], Aihua Zheng[SUP] 1 2 7 [/SUP]
Affiliations
- PMID: 35071273
- PMCID: PMC8777026
- DOI: 10.3389/fmed.2021.793437
Abstract
SARS-CoV-2 is an emerging coronavirus threatening human health and the economy worldwide. As an RNA virus, variants emerge during the pandemic and potentially influence the efficacy of the anti-viral drugs and vaccines. Eight spike variants harboring highly recurrent mutations were selected and introduced into a replication-competent recombinant VSV in place of the original G protein (rVSV-SARS-CoV-2). The resulting mutant viruses displayed similar growth curves in vitro as the wild-type virus and could be neutralized by sera from convalescent COVID-19 patients. Several variants, especially Beta strain, showed resistance to human neutralizing monoclonal antibodies targeting the receptor-binding domain (RBD). A single dose of rVSV-SARS-CoV-2 Beta variant could elicit enhanced and broad-spectrum neutralizing antibody responses in human ACE2 knock-in mice and golden Syrian hamsters, while other mutants generated antibody levels comparable to the wild-type. Therefore, our results will be of value to the development of next-generation vaccines and therapeutic antibodies.
Keywords: SARS-CoV-2; VSV; antigenicity; immunogenicity; infectivity; mutation; spike; variant